Virtual Library
Start Your Search
T. Abe
Author of
-
+
P1.14 - Radiotherapy (ID 700)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Radiotherapy
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.14-006 - Carbon-Ion Radiotherapy for Isolated Lymph Node Metastasis from Lung Cancer Using a Regimen of 12 Fractions during 3 Weeks (ID 7451)
09:30 - 09:30 | Author(s): T. Abe
- Abstract
Background:
Mediastinal and hilar lymph node metastases after definitive treatment for lung cancer is one of the main recurrence. Generally, isolated lymph node metastases without other recurrence are treated with local treatment, such as radiotherapy and surgery. Carbon-ion radiotherapy has a superior dose distribution and higher biological effectiveness compared with photon therapy. We retrospectively evaluated the efficacy and safety of hypofractionated carbon-ion radiotherapy for isolated lymph node metastasis in lung cancer patients.
Method:
Between April 2013 and August 2016, 15 patients were treated with carbon-ion radiotherapy. Median age was 72 years old (range: 51-83), and male patients were 11 (73%). Initial treatments were carbon-ion radiotherapy (n=8) and surgery (n=7). Pathological types were adenocarcinoma (n=9), squamous cell carcinoma (n=4), and others (n=2), respectively. All patients were treated using 12 fractions over 3 weeks. Fourteen patients received 52.8 Gy (relative biological effectiveness [RBE]) in and 1 patients received 48.0 Gy (RBE). Local control, progression free survival, and overall survival rates were statistically calculated by the Kaplan-Meier method. Acute and late adverse events were evaluated according to the Common Terminology Criteria for Adverse Events, version 4.0. This retrospective study was reviewed and approved by our Institutional Review Board.
Result:
The median follow-up time was 14 months. One patient had local lymph node failure, and the 1-year local control rate was 90%. This patient had a primary tumor recurrence, accompanied with lymph node failure at the same time. Three patients died of lung cancer, and the 1-year OS rate was 93%. Distant metastases were observed in 6 patients, and the 1-year PFS were 64%. Acute grade 2 esophagitis and grade 2 cough were observed in 2 (13%) and 2 (13%) patients, respectively. These acute adverse events were immediately improved by conservative therapy. There were no patients with grade ≧2 pneumonitis.
Conclusion:
Although follow-up period was short, hypofractionated carbon-ion radiotherapy showed great local control and overall survival without severe toxicities in lung cancer patients with isolated lymph node metastasis. Carbon-ion radiotherapy is considered an option of salvage treatment for isolated lymph node metastasis. Further follow-up is required to evaluate local control, overall survival, and late adverse events.
